Kornimate/medical-research-clean huggingface dataset:
comparing effects of kinesio and dynamic tapings in postpartum women with pelvic girdle pain

Conditions: Pelvic Girdle Pain

Summary: about 45% of pregnant women and 25% of women postpartum suffer from pelvic girdle pain. pain is often reported to be localized between costal margin and gluteal fold with or without radiation to lower limb or symphysis pubic. kinesio taping (kt) is the application of an elastic tape, for treating musculoskeletal conditions through enhancing muscle strength, relieving spasms, pain and edema, improving blood circulation and lymph reflux, as well as stabilizing joints. however, with limited evidence and a lack of well-designed study, the effects of kt in postpartum women with pgp remains unclear. compared with kt, the dynamic taping(dt) is recently developed and has stronger elastic resistance and recoil. the dt may have better effects than the kt, although this notion has not been examined. in this study, we make a hypothesis that pgp women in the dt group would have better improvements on pain, disability, quality of life, and pfm functions than that in the kt group and control group.

the main purpose for this study are to investigate the effects of kt and dt on pain, disability, physical functions, and quality of life, as well as pfm functions in postpartum women with pgp. 60 postpartum women with pgp will be randomized into one of the three groups:(1) kinesio taping group,(2) dynamic taping group (3)control group, and receive 4 weeks intervention. all participants will receive 3 assessments at the baseline, immediately after first taping session, and after 4-week interventions. the outcome measures will include visual analog scale measures of pain intensity, pelvic girdle questionnaire/ oswestry disability index/ patient specific functional scale measures and global rating of change score. for disability. the quality of life will be measured by 36-item short-form survey， the physical functions include active straight leg raise fatigue task , time up and go test,10-meter walk test. the pfm functions will be measured by modified oxford grading scale and perineometer. it is expected that pgp women in both the kt group and dt group will have more improvements than the control group. but the dt group will have even more improvements than the kt groups.

Eligibility criteria:
inclusion criteria: 1. age: \> 20 year 2. postpartum:≥ 3 months 3. pain onset during pregnancy 4. pain location is located between costal margin and gluteal fold with or without radiation to lower limb or symphysis pubic 5. clinical screening test for pelvic pain : active straight leg raising : positive * 2 (+) posterior pelvic pain provocation tests (+ symphysis ≥ 1) exclusion criteria: 1. bmi ≥ 30 2. lumbar or pelvic surgery 3. history of fracture 4. radiculopathy or myopathy 5. gynaecological disorders 6. serious cardiovascular disease 7. tumors 8. diagnosed psychiatric disease 9. ongoing pregnancy 10. allergy to acrylic

Keywords: kinesio taping dynamic taping postpartum
comparative evaluation of pulpal anaesthetic efficacy of different anaesthetic solutions for inferior alveolar nerve block in patients with symptomatic irreversible pulpitis

Conditions: Pulpitis

Summary: pulpal and periapical inflammation and infection can cause tissue ph in the affected region to be lowered which results in less penetration of anesthetic solution in the nerve membrane and hence delays the onset of anesthesia. so, the purpose of this study was to compare the pulpal anesthetic efficacy of lidocaine, articaine, mepivacaine for inferior alveolar nerve block (ianb) in patients with irreversible pulpitis (ip). one hundred and twenty adult patients with ip concerning mandibular molars randomly received ianb with either of the three solutions: 2% lidocaine with epinephrine; 4% articaine with epinephrine; 3% plain mepivacaine. pain during the endodontic treatment was assessed using a visual analog scale (heft-parker vas). endodontic treatment was initiated. success was defined as no or mild pain (pain score≤54mm on hp vas) during access preparation and root canal instrumentation. the anesthetic success rates were analyzed with the chi-square test.


Eligibility criteria:
inclusion criteria: * active pain in a mandibular molar * prolonged response to cold testing with an ice stick and an electric pulp tester * absence of any periapical radiolucency on radiographs, except for a widened periodontal ligament * vital coronal pulp on access opening and ability to understand the use of pain scales exclusion criteria: * known allergy, sensitivity, or contraindications to any opioid or nonopioid analgesic including aspirin or nsaids * history of active peptic ulcer within the preceding 12 months * history of bleeding problems or anticoagulant use within the last month * patients who were pregnant or breast-feeding * a history of known or suspected drug abuse * patients who had taken nsaids within 12 h before administration of the study drugs
68ga psma 11 pet/mri and 68ga rm2 pet/mri for biopsy guidance in patients with suspected prostate cancer

Conditions: Prostate Cancer

Summary: the objective of the study is to evaluate 68ga psma 11 pet/mri and 68ga rm2 pet/mri for biopsy guidance in patients with suspected prostate cancer.

primary objective: to evaluate 68ga psma 11 pet/mri and 68ga rm2 pet/mri for biopsy guidance in patients with suspected prostate cancer. exploratory objective: * correlation of 68ga psma 11 uptake and gleason score at biopsy * correlation of 68ga rm2 and gleason score at biopsy

Eligibility criteria:
inclusion criteria: * suspected prostate cancer * planned prostate biopsy * able to provide written consent * karnofsky performance status of 50 (or ecog/who equivalent) exclusion criteria: * patients not capable of getting pet study due to weight, claustrophobia, or inability to lay still for the duration of the exam * metallic implants (contraindicated for mri)

Keywords: prostate cancer
combination therapies with adagrasib in patients with advanced nsclc with kras g12c mutation

Conditions: Advanced NSCLC; Metastatic Lung Cancer

Summary: study ca239-0010 is an open-label, phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced nsclc with tps ≥ 1%, tps \<50% and kras g12c mutation


Eligibility criteria:
cohort a\* (closed): has an untreated and unresectable or metastatic nsclc with histologically confirmed (squamous or nonsquamous) krasg12c mutation and histologically confirmed pd-l1 tps ≥1%. * cohort c: has an untreated and unresectable or metastatic nsclc with histologically confirmed (non-squamous only) krasg12c mutation and histologically confirmed pd-l1 tps \< 50% and previously completed 4 cycles of standard-of-care platinum based induction chemotherapy with pembrolizumab and experienced stable disease, partial response, or complete response per investigator's assessment after 4 cycles or if patients received \<4 cycles of a platinum-based induction, was stopped early due to intolerable toxicity * cohort e: has an untreated and unresectable or metastatic nsclc with histologically confirmed (non-squamous only) krasg12c mutation and histologically confirmed pd-l1 tps \< 50% * presence of measurable disease per recist v1.1 exclusion criteria: * all cohorts: any prior therapy targeting krasg12c mutation in any setting * cohorts a \& e: prior systemic therapy for locally advanced or metastatic nsclc, including chemotherapy, immune checkpoint inhibitor therapy or chemoimmunotherapy (note: prior systemic therapy or chemoradiation given in the adjuvant or neoadjuvant setting are allowed if last dose of prior systemic treatment was \>1 year prior to first dose of study treatment) * cohort c: received maintenance therapy (e.g, pembrolizumab and/or pemetrexed following completion of 4-6 cycles of a platinum-based regimen administered in the first-line setting * radiation to the lung \> 30 gy within 6 months prior to first dose of study treatment * active brain metastases

Keywords: kras g12c nsclc non small cell lung cancer
the pk/pd study of shr0532 tablets in healthy subjects

Conditions: Hypertension

Summary: in the last four decades, several classes of diuretics have been the first line option for the therapy of widespread hypertension. however, all the classes of diuretics cause alteration of potassium homeostasis. the primary objective of this study is to assess the safety and tolerability of shr0532 tablets in healthy subjects. in addition, this study will provide information on pharmacokinetics and pharmacodynamics of shr0532 tablets in healthy subjects.


Eligibility criteria:
inclusion criteria: 1. males or females, aged 18-45 2. subjects have no cardiovascular disease, with sitting blood pressure: 90mmhg ≤sbp\<140mmhg and 60mmhg ≤dbp\<90mmhg; 3. body mass index (bmi) between 19 to 26, and a total body weight: male ≥50.0 kg and \<90.0 kg; female ≥45.0 kg and \<90.0 kg 4. participant in general good health. no clinically significant findings in laboratory parameters or clinically significant abnormality on electrocardiogram, x-ray, echocardiograph and b-type ultrasonic exclusion criteria: 1. alanine aminotransferase (alt) or aspartate aminotransferase (ast) or total bilirubin \> 1.5 x uln during screening/baseline; 2. serum creatinine\>uln)during screening/baseline; 3. human immunodeficiency virus antibody (hiv-ab), syphilis serological examination, hepatitis b virus surface antigen (hbsag), hepatitis c virus antibody (hcv-ab) test positive; 4. known postural hypotension; the numeric difference of systolic blood pressure between both upper limbs \>20mmhg； 5. a clinical history of arrhythmia；subjects with electrocardiogram qtc prolongation（male\>450ms；female\>460ms）during screening； 6. a clinical history of hyperuricemia；serum uric acid \> the upper limit of normal value (uln) during screening; 7. a clinical history of diabetes；fasting plasma glucose or hemoglobin a1c exceeded the upper limit of normal value (uln) during screening; 8. subjects with previous gi discomfort -abdominal pain, diarrhea, and nausea 3 months prior to screening； 9. a clinical history of acute or chronic kidney disease; 10. subjects with severe trauma or surgery within 3 months prior to the screening； 11.3 months prior to screening involved in any drug or medical device clinical subjects, or within 5 half-life of drugs (test drug half-life more than 3 months) before screening; 12.pregnant or serum β-hcg \> 5miu/ml at baseline or women who are breastfeeding; etc.
g-pur® for reduced dietary fumonisin bioavailability

Conditions: Reduction of Dietary Fumonisin Bioavailability

Summary: this prospective, placebo-controlled, randomized, monocentric, double-blind, crossover study in healthy volunteers aims to assess the effect of a single dose of 2 g g-pur® on bioavailability of dietary fumonisin and to evaluate safety and tolerability.


Eligibility criteria:
inclusion criteria: 1. healthy male and female subjects 2. age 18-55 years 3. bmi 17-27 4. subjects are in good clinical and mental health as established by medical history and physical examination 5. subject understands the scope of the study and agrees to strictly adhere to the study related diet plan 6. written informed consent exclusion criteria: 1. pregnancy or breastfeeding. 2. lack of willingness or capacity to co-operate appropriately 3. regular use of medications in the previous 2 months (except oral contraception) 4. history of malignancies within the past two years or on current anticancer treatment 5. history of gastrointestinal pathology such as clinically relevant gastritis, gastric ulcers, inflammatory bowel disease, chronic constipation 6. history of diarrhoea within the past 14 days of screening 7. history of gastrointestinal surgery with exception of appendectomy 8. history of any chronic liver disease 9. history of autoimmune disease requiring treatment within the past two months of screening 10. known symptomatic food allergies 11. active infection (including hiv and hepatitis b or c), or abnormalities in laboratory testing, vital signs, or physical examination 12. hypersensitivity to aluminium and/or silicon 13. chronic renal disease requiring dialysis 14. alcohol, cigarette or drug abuse 15. presence of any condition that impacts compliance with the study procedures 16. use of any investigational or non-registered product (drug or device) within 30 days preceding the first study product administration, or planned use during the study period 17. employee at the study site, spouse/partner or relative of any study staff (e.g. investigator, sub-investigators, or study nurse) or relationship to the sponsor
lipid management in clinical practice (mk-0524a-115)

Conditions: Lipid Metabolism Disorder

Summary: the aim of this observational program is to generate data on the use of tredaptive (nicotinic acid/laropiprant) for lipid management under routine medical practice conditions.


Eligibility criteria:
inclusion criteria: * patients are 18 years of age or older with lipid disorder treated with nicotinic acid/laropiprant exclusion criteria: * patient is currently participating in a clinical trial

Keywords: lipid metabolism disorder
short course radiotherapy combined with chemotherapy in stage iv rectal cancer with resectable liver metastases

Conditions: Stage IV Rectal Cancer, Liver Metastasis, Resectable

Summary: patients with rectal cancer and resectable liver metastases receive short course radiotherapy(5gy/f x 5f) to the pelvis and xelox consolidating chemotherapy al least 4 cycles after 2 weeks.

patients with rectal cancer and resectable liver metastases receive 25 gy in 5 fractions of 5 gy over 5 days to the pelvis and xelox consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks. after evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. those patients with unresectable lesions will receive chemotherapy.

Eligibility criteria:
inclusion criteria: * histologically confirmed primary carcinoma of the rectum (lower border of tumour ≤ 10 cm from anal verge) locally advanced stage in primary site of rectum resectable synchronous liver metastases. the decision of resectable liver metastases will be made at multidisciplinary clinical meetings. exclusion criteria: * obstruction of the gastrointestinal tract previously constructed stoma prior radiotherapy of the pelvis
a study of tak-360 in adults with idiopathic hypersomnia

Conditions: Idiopathic Hypersomnia

Summary: idiopathic hypersomnia (ih) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. they may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feeling tired, even after taking daytime naps. because of this sleepiness, they may have trouble focusing, thinking clearly, or keeping up with daily activities. they may also have symptoms like dizziness or feeling lightheaded. orexin is a chemical made in the brain that helps keep a person awake and alert. tak-360 acts like orexin. previous studies have shown that medicines that act like orexin may keep people awake. the main aim of this study is to learn how safe tak-360 is and how well adults with ih tolerate it. researchers also want to find out if tak-360 can help people with ih stay awake and how much tak-360 is needed to do that. participants will be randomly (by chance, like drawing names from a hat) chosen to receive either tak-360 or a placebo. the placebo looks just like tak-360 but does not have any medicine in it. using a placebo helps researchers learn about the real effect of the treatment.


Eligibility criteria:
key inclusion criteria: 1. the participant weighs greater than or equal to (≥) 40 kilograms (kg) and has a body mass index (bmi) between 16 and 38 kilograms per meter square (kg/m\^2) \[inclusive\]. 2. the participant has a documented, current diagnosis of ih. key exclusion criteria: 1. the participant has a current medical disorder associated with excessive daytime sleepiness (eds) \[other than ih\]. 2. the participant has medically significant thyroid disease. 3. the participant has a history of cancer in the past 5 years. (this exclusion does not apply to participants with carcinoma in situ \[such as basal cell carcinoma\] that has been treated and is stable, or who have been stable without further treatment. these participants may be included after approval by the medical monitor.) 4. the participant has any of the following viral infections based on a positive test result: hepatitis b surface antigen (at screening), hepatitis c virus antibody (at screening), human immunodeficiency virus (hiv) antibody/antigen (at screening). 5. the participant has a clinically significant history of head injury or head trauma. 6. the participant has history of epilepsy, seizure, or convulsion (exception for a single febrile seizure in childhood). 7. the participant has a history of cerebral ischemia, transient ischemic attack (less than \[\<\]5 years from screening), intracranial aneurysm, or arteriovenous malformation.

Keywords: idiopathic hypersomnia tak-360
ideal time of stenting prior to ureteral access sheath for stone disease

Conditions: Ureteric Stone

Summary: the miniaturization of endourological instruments and improvements in laser lithotripsy have revolutionized the approach to renal stones . - flexible urs has become popular with urologists, as it is easy to learn, is associated with high stone-free rates, and is acceptable to patients. firstly described in 1964 by marshall, the uretroscope was only passively deflectable and did not include working channel. - although the first successful procedure in humans with a ureteroscope integrating active deflection has been reported by takayasu, it was not until 1987 that demetrius bagley introduced flexible ureteroscopy as we know it today ).\] - two types of flexible uretroscopy can be distinguished : fiberoptic and digital flexible urs. the difference between them is the image relay and light transmission. - now either to use ureteral access sheath (as) or not , but usage of as decrease intrarenal pressure and clear vision by drainage of dust , so , for access of as stent better to be inserted prior to the procedure ) so, there are little publications regarding the optimal timing of the stent in this study we will assess the feasibility of passage as after two versus four weeks from stent insertion

the miniaturization of endourological instruments and improvements in laser lithotripsy have revolutionized the approach to renal stones . - flexible urs has become popular with urologists, as it is easy to learn, is associated with high stone-free rates, and is acceptable to patients. firstly described in 1964 by marshall, the uretroscope was only passively deflectable and did not include working channel. - although the first successful procedure in humans with a ureteroscope integrating active deflection has been reported by takayasu, it was not until 1987 that demetrius bagley introduced flexible ureteroscopy as we know it today ).\] - two types of flexible uretroscopy can be distinguished. the difference between them is the image relay and light transmission. - now either to use ureteral access sheath (as) or not , but usage of as decrease intrarenal pressure and clear vision by drainage of dust , so , for access of as stent better to be inserted prior to the procedure ) so, there are little publications regarding the optimal timing of the stent in this study we will assess the feasibility of passage as after two versus four weeks from stent insertion

Eligibility criteria:
inclusion criteria: * all patients with stone kidney up to 2 cm * failed eswl (extracorporeal shock wave lithotripsy) * difficult pcnl (percutaneous nephrolithotomy) exclusion criteria: * size more than 2 cm
combined pecs ii and transeversus thoracic plane blocks vs serratus anterior plane block in modified radical mastectomy

Conditions: Ultrasound-Guided; Transeversus Thoracic Plane Blocks; Pectoral Nerve (PECS) Block; Serratus Anterior Plane Block; Modified Radical Mastectomy

Summary: the aim of this study is to evaluate the analgesic efficacy of combined ultrasound (us)-guided pectoral nerve (pecs) block ii and transversus thoracic plane (ttp) block versus us-guided serratus anterior plane (sap) block in female patients undergoing modified radical mastectomy.


Eligibility criteria:
inclusion criteria: * female patients * aged 21-60 years * asa physical status i, ii * scheduled for unilateral modified radical mastectomy exclusion criteria: 1. patient refusal. 2. known hypersensitivity to local anesthetics. 3. body mass index \> 35 kg /m2. 4. uncooperative or psychiatric patients. 5. infection at the injection site. 6. coagulation disorder.
non-invasive identification of preoperative anaemia

Conditions: Anemia

Summary: approximately 20% of patients undergoing elective orthopaedic surgery are anaemic. when not identified and treated before surgery, this can lead to requiring blood transfusions, which brings additional expenses, time and inconvenience to the patient.it is recommended that preoperative assessment involves investigation and where possible, treatment of anaemia. the timescale between assessment and surgery makes it difficult to comply with guidelines without postponing surgery. this study will investigate adult patients scheduled for elective orthopaedic surgery, where a full blood count is to be taken as part of routine care. a paired non-invasive reading of their blood will be taken. it will be conducted at the royal infirmary, edinburgh. this device is not in use within the department currently but has been given free of charge for the study. there are no restrictions placed on the device except that it is not accurate for measuring haemoglobin \<8g.dl. participant care will only be determined by results from the laboratory assay as per routine care, not the noninvasive device. the device is ce marked for haemoglobin determination. masimo (manufacturer) have released results in the accuracy of their monitor but with very little other information, for example, study population or precision. this study aims to answer how accurate and precise non-invasive measurements are in patients scheduled for orthopaedic surgery (there are no studies with these results) and whether anaemia can be identified earlier in the patient pathway i.e. an anaemia screen at time of surgical listing, therefore leaving ample time for treatment and optimisation of care. the data from the study will not be shared with masimo. there is ongoing work towards introducing and piloting a new pre-operative triage system where optimisable conditions e.g. anaemia are identified at the time of listing. this study would aid this work.


Eligibility criteria:
inclusion criteria: * able to provide informed consent * aged between 16-80 years old * scheduled for elective orthopaedic surgery * a full blood count (fbc) is to be taken as part of routine care inclusion criteria for healthy volunteers cohort: * able to provide informed consent * aged between 16-80 years old exclusion criteria: * patients with haemoglobin disorders * raynaud's disease (or any other condition affecting the blood supply to the digits). exclusion criteria for healthy volunteers cohort: * patients with haemoglobin disorders * raynaud's disease (or any other condition affecting the blood supply to the digits).